Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxg1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	OCT 03	MATHDI removed from STN
NEWS	9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	10	OCT 06	STN AnaVist workshops to be held in North America
NEWS	11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:18:44 ON 25 OCT 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:18:53 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2005 HIGHEST RN 865981-77-7
DICTIONARY FILE UPDATES: 24 OCT 2005 HIGHEST RN 865981-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical Data\10531676\compound.str





chain nodes :
6 7 8 9 10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5
chain bonds :
2-6 6-7 7-8 7-9 7-10 9-15 9-16 9-17 10-11 10-14 12-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 4-5 7-8 12-13
exact bonds :
6-7 7-9 7-10
normalized bonds :
9-15 9-16 9-17 10-11 10-14

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

```
L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 17:19:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        9 TO ITERATE

100.0% PROCESSED        9 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            9 TO      360
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l2 full
FULL SEARCH INITIATED 17:19:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      189 TO ITERATE

100.0% PROCESSED      189 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.76     161.97

FILE 'CAPLUS' ENTERED AT 17:20:08 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Oct 2005  VOL 143 ISS 18
FILE LAST UPDATED: 24 Oct 2005  (20051024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L4            0 L2

=> file medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.45     162.42
```

```
FILE 'MEDLINE' ENTERED AT 17:20:16 ON 25 OCT 2005

 FILE LAST UPDATED: 22 OCT 2005 (20051022/UP).  FILE COVERS 1950 TO DATE.

 On December 19, 2004, the 2005 MeSH terms were loaded.

 The MEDLINE reload for 2005 is now available.  For details enter HELP
 RLOAD at an arrow promt (=>).  See also:

    http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

 OLDMEDLINE now back to 1950.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2005 vocabulary.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s "1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid"
       3573531 "1"
         61380 "HYDROXY"
       3130230 "2"
          1357 "IMIDAZOL"
       3573531 "1"
         18868 "YL"
          6223 "ETHANE"
       3573531 "1"
       3573531 "1"
           123 "DIPHOSPHONIC"
       1360069 "ACID"
L5           0 "1-HYDROXY-2-(IMIDAZOL-1-YL)ETHANE-1,1-DIPHOSPHONIC ACID"
               ("1"(W)"HYDROXY"(W)"2"(W)"IMIDAZOL"(W)"1"(W)"YL"(W)"ETHANE"(W)
               "1"(W)"1"(W)"DIPHOSPHONIC"(W)"ACID")

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.76     163.18

FILE 'REGISTRY' ENTERED AT 17:21:36 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 OCT 2005  HIGHEST RN 865981-77-7
DICTIONARY FILE UPDATES:  24 OCT 2005  HIGHEST RN 865981-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
```

* available and contains the CA role and document type information. *
*   *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical Data\10531676\compound1.str





chain nodes :
6 7 8 9 10
ring nodes :
1 2 3 4 5
chain bonds :
2-6 6-7 7-8 7-9 7-10
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 4-5 7-8
exact bonds :
6-7 7-9 7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L6 . STRUCTURE UPLOADED

=> s l6
SAMPLE SEARCH INITIATED 17:21:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 2 TO 124

L7 2 SEA SSS SAM L6

=> s l7 full
FULL SEARCH INITIATED 17:21:54 FILE 'REGISTRY'

```
FULL SCREEN SEARCH COMPLETED -      101 TO ITERATE

100.0% PROCESSED      101 ITERATIONS                                47 ANSWERS
SEARCH TIME: 00.00.01

L8            47 SEA SSS FUL L6

=> s l8 and rheumatoid
           149 RHEUMATOID
L9           0 L8 AND RHEUMATOID

=> s l8 and arthritis
           286 ARTHRITIS
L10          0 L8 AND ARTHRITIS

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   171.82     335.00

FILE 'REGISTRY' ENTERED AT 17:23:47 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 OCT 2005  HIGHEST RN 865981-77-7
DICTIONARY FILE UPDATES:  24 OCT 2005  HIGHEST RN 865981-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical
Data\10531676\compound2.str
```





chain nodes :
6 7 8 9 10 11 12 13 14 15 16
ring nodes :
1 2 3 4 5
chain bonds :
2-6 6-7 7-8 7-9 7-13 9-10 9-11 9-12 13-14 13-15 13-16
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 4-5 7-8
exact bonds :
6-7 7-9 7-13
normalized bonds :
9-10 9-11 9-12 13-14 13-15 13-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L11 STRUCTURE UPLOADED

=> s l11
SAMPLE SEARCH INITIATED 17:23:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 2 TO 124

L12 2 SEA SSS SAM L11

=> s l12 full
FULL SEARCH INITIATED 17:24:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 189 TO ITERATE

100.0% PROCESSED 189 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

L13 39 SEA SSS FUL L11

=> s l13 (L) arthritis
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L13 (L) ARTHRITIS'
286 ARTHRITIS

```
L14           0 L13 (L) ARTHRITIS

=> s l13 and ?immune?
LEFT TRUNCATION IGNORED FOR '?IMMUNE?' FOR FILE 'REGISTRY'
         54684 IMMUNE?
L15           0 L13 AND ?IMMUNE?
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> s l13 and ?immune
LEFT TRUNCATION IGNORED FOR '?IMMUNE' FOR FILE 'REGISTRY'
         54673 IMMUNE
L16           0 L13 AND ?IMMUNE
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> s l13 and (immune or autoimmune)
         54673 IMMUNE
            93 AUTOIMMUNE
L17           0 L13 AND (IMMUNE OR AUTOIMMUNE)

=> s l13
SAMPLE SEARCH INITIATED 17:25:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        9 TO ITERATE

100.0% PROCESSED         9 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             9 TO      360
PROJECTED ANSWERS:                2 TO      124

L18            2 SEA SSS SAM L11

=> s l13 full
FULL SEARCH INITIATED 17:26:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      189 TO ITERATE

100.0% PROCESSED       189 ITERATIONS                             39 ANSWERS
SEARCH TIME: 00.00.01

L19           39 SEA SSS FUL L11

=> d 30-39 bib abs hitstr
'BIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> s l13
SAMPLE SEARCH INITIATED 17:26:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             9 TO      360
PROJECTED ANSWERS:                2 TO      124

L20          2 SEA SSS SAM L11

=> s l20 full
FULL SEARCH INITIATED 17:26:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      189 TO ITERATE

100.0% PROCESSED      189 ITERATIONS                                39 ANSWERS
SEARCH TIME: 00.00.01

L21          39 SEA SSS FUL L11

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     507.85     842.85

FILE 'CAPLUS' ENTERED AT 17:26:47 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Oct 2005  VOL 143 ISS 18
FILE LAST UPDATED: 24 Oct 2005  (20051024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l21
L22         470 L21

=> s l22 and rheumatoid
          26974 RHEUMATOID
L23          22 L22 AND RHEUMATOID

=> s l23 and arthritis
          38537 ARTHRITIS
L24          22 L23 AND ARTHRITIS

=> d 1-22 bib abs hitstr

L24  ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2005:673327  CAPLUS
DN   143:171327
TI   M-CSF-specific monoclonal antibody and derivatives or fragments for drug
     screening and treatment of osteolytic disease, bone loss, cancer and
     metastasis
IN   Liu, Cheng; Zimmerman, Deborah Lee; Harrowe, Gregory Martin; Koths,
     Kirston; Kavanaugh, William Michael; Long, Li; Calderon-Cacia, Maria;
```

Horwitz, Arnold H.
PA Chiron Corporation, USA; Xoma Technology Ltd.
SO PCT Int. Appl., 283 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005068503	A2	20050728	WO 2005-US546	20050106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-535181P	P	20040107	
US 2004-576417P	P	20040602	

AB M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compns. containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease. These antibodies include chimeric antibodies, humanized antibodies, human engineered antibodies, human antibody, antibody conjugates and fragments. Compns. comprising the antibody may also contain a second therapeutic agent, e.g. cancer chemotherapeutic agent such as a bisphosphonate.

IT **118072-93-8**, Zoledronate
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(M-CSF-specific monoclonal antibody and derivs. or fragments for drug screening and treatment of osteolytic disease, bone loss, cancer and metastasis)
RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:259887 CAPLUS
DN 142:336518
TI Preparation of 17β-heterocyclic-3-oxo-4-aza-5α-androst-1-ene derivatives as androgen receptor modulators
IN Meissner, Robert S.; Mitchell, Helen J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005025579	A1	20050324	WO 2004-US28641	20040902
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-501664P	P	20030910		
OS	MARPAT 142:336518				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention discloses preparation of 17β-heterocyclic-3-oxo-4-aza-5α-androst-1-ene derivs., such as I [dashed bond = single bond, double bond; X = H, halo; Y, Z = H, alkyl, halo; Y and Z, together with the carbon atom to which they are attached = cyclopropyl; n = 0-3; U, V, W, D = CH, N, provided that at least U, V, W, and D = CH; R1 = H, CF3, carbonyl(alkyl), OH, alkoxy, halo, alkyl, CH2OH, alkylamino; R2 = halo, carbonyl(alkyl), carbonyl(alkenyl), carbonyl(alkynyl), alkenylamino, heterocyclic, etc.], for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, 4-azaandrost-1-ene derivative II was reacted with 2,3-diaminopyridine in presence of silver triflate to give 17β-carboxamide derivative III, which, on heating with polyphosphoric acid, afforded 17β-imidazopyridinyl-3-oxo-4-aza-5α-androst-1-ene derivative IV. I are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory **arthritis** and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

IT **118072-93-8**, Zoledronate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of 17β-heterocyclic-3-oxo-4-aza-5α-androst-1-ene derivs. as androgen receptor modulators and their therapeutic uses)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:259881 CAPLUS
DN 142:336517
TI Preparation of 17-heterocyclic-4-aza-5α-androst-1-en-3-one derivatives for their use as modulators of the androgen receptor in a tissue selective manner
IN Kaufman, Mildred L.; Meissner, Robert S.; Mitchell, Helen J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005025572	A1	20050324	WO 2004-US28655	20040902
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-501789P	P	20030910		

OS MARPAT 142:336517
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 17-Heterocyclic-4-aza-5α-androst-1-en-3-one derivs., such as I [dashed bond = single bond, double bond; X = H, halo; Y, Z = H, alkyl, halo; Y and Z, together with the carbon atom to which they are attached = cyclopropyl; n = 0-3; U, V, W, D = CH, N, S, O; R1 = H, CF3, carbonyl(alkyl), OH, alkoxy, halo, alkyl, CH2OH, alkylamino; R2 = halo, carbonyl(alkyl), carbonyl(alkenyl), carbonyl(alkynyl), alkenylamino, heterocyclic, etc.], were prepared for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, II (R = OH) was treated with Et3N, and iso-Bu chloroformate, followed by reaction with N,O-dimethylhydroxylamine hydrochloride to give II [R = N(Me)OMe (III)]. III was converted to 4-aza-5α-androst-1-en-3,20-dione derivative II (R = Me), and then to bromide II [R = CH2Br (IV)], which was treated with N-butyl-thiourea to afford V. The prepared compds. are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen

administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory **arthritis** and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

IT **118072-93-8**, Zoledronate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of 17-heterocyclic-4-aza-5α-androst-1-en-3-one derivs. as androgen receptor modulators and their therapeutic uses)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:220135 CAPLUS
DN 142:274037
TI Pyrimidine and pyridine derivatives as glycogen synthase kinase 3 (GSK-3) inhibitors for treating or preventing bone loss
IN Bennett, Christina N.; Hankenson, Kurt D.; Harrison, Stephen D.; Longo, Kenneth A.; Macdougald, Ormond A.; Wagman, Allan S.
PA USA
SO U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005054663	A1	20050310	US 2004-917707	20040813
	WO 2005039485	A2	20050506	WO 2004-US26355	20040813
	WO 2005039485	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-494859P P 20030813

OS MARPAT 142:274037

AB This invention relates to methods of treating or preventing bone loss by administering to a human or animal subject pyrimidine and pyridine derivs. that inhibit the activity of glycogen synthase kinase 3 (GSK3), to pharmaceutical compns. containing the compds., and to the use of the compds. and compns. alone or in combination with other pharmaceutically active agents. Bone loss is prevented or treated with 6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methylimidazol-2-yl)pyrimidin-2-yl]amino]ethyl]amino]pyridine-3-carbonitrile (prepared from 2,4-dichlorobenzoyl chloride and 2,4-dimethylimidazole).

IT **118072-93-8**, Zoledronic acid
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with; pyrimidine and pyridine derivs. as glycogen synthase kinase 3 inhibitors for treating or preventing bone loss)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:122803 CAPLUS

DN 142:219083

TI Preparation of phosphorus-containing rapamycin derivatives for use in pharmaceutical compositions as immunosuppressive and anticancer agents

IN Metcalf, Chester A.; Rozamus, Leonard W.; Wang, Yihan; Berstein, David L.

PA USA

SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 635,054.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005032825	A1	20050210	US 2004-862149	20040604
	US 2003220297	A1	20031127	US 2003-357152	20030203
	US 2004073024	A1	20040415	US 2003-635054	20030806
PRAI	US 2002-353252P	P	20020201		
	US 2002-426928P	P	20021115		
	US 2002-428383P	P	20021122		
	US 2002-433930P	P	20021217		
	US 2003-357152	A2	20030203		
	US 2003-635054	A2	20030806		

OS MARPAT 142:219083

GI



I

AB Rapamycin derivs. containing phosphorus moiety, such as I [A = O, S, NR2, absent; Q = V, OV, SV, NR2, absent; V = aliphatic, heteroaliph., aryl, heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR2VA; J = P(:K)(YR5)2, P(YR5)2, P(:K)(YR5)GR6; K = O, S; Y = O, S, NR2, bond; R2, R5 = aliphatic, heteroaliph., aryl, heteroaryl, H; R6 = PK(YR5)YR5, SO2YR5, C(O)YR5; G = O, S, NR2, (M)X; M = (un)substituted methylene, alkyl, alkylene; X = 1-6], and pharmaceutically acceptable derivs. thereof, were prepared for therapeutic use as immunosuppressive and anticancer agents. These rapamycin derivs. are useful for treatment of graft vs. host disease, lupus, **rheumatoid arthritis**, diabetes mellitus, myasthenia gravis, multiple sclerosis, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation, ocular uveitis; adult T-cell leukemia, lymphoma, fungal infections, hyperproliferative restenosis, graft vascular atherosclerosis, coronary artery disease, cerebrovascular disease, arteriosclerosis, atherosclerosis, nonatheromatous arteriosclerosis, or vascular wall damage from cellular events leading toward immune mediated vascular damage, stroke or multi-infarct dementia. Thus, I [A-QJ = OP(O)(OBu)Me] was prepared by reacting rapamycin with methylphosphonic dichloride and n-butanol using 3,5-lutidine in CH2Cl2 under a nitrogen atmospheric Binding affinity of the rapamycin phosphorus derivs. for human FKBP-12 protein was assayed, dosages for restenosis prevention were discussed.

IT **118072-93-8**, Zoledronate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of phosphorus-containing rapamycin derivs. for use in pharmaceutical compns. as immunosuppressive and anticancer agents)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:58320 CAPLUS
DN 142:156210
TI Preparation of 3-oxo-4-aza-5α-androst-1-ene-17β-acetamide derivatives as androgen receptor modulators
IN Dankulich, William P.; Kaufman, Mildred L.; Meissner, Robert S.; Mitchell, Helen J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005005606	A2	20050120	WO 2004-US20539	20040625
WO 2005005606	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-483675P P 20030630
OS MARPAT 142:156210
GI



I



II

AB 3-Oxo-4-aza-5α-androst-1-ene-17β-acetamide derivs., such as I [X = H, halo; Z = H, CF3, carbonylalkyl, alkyl, alkoxy, halo, CH2OH; A = aromatic ring having 0-4 heteroatoms; polycyclic ring system having one or more aromatic rings and 0-4 heteroatoms; R1, R2, R3, R4, R5 = H, halo, alkyl, amino, alkylamino, aminoalkyl, alkoxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, cyano, perfluoroalkyl, alkylcarbonyl, alkylcarbonylamino, etc.; R1R2, R3R4 = oxo, spirocycloalkyl], or a pharmaceutically acceptable salt or an enantiomer thereof, were prepared for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, 3-oxo-4-aza-5α-androst-1-ene-17β-acetamide derivative II, was prepared via a multiple step reaction sequence starting from 4-methyl-3-oxo-4-aza-5α-androst-1-ene-17-carboxylic acid and 2-aminomethylpyridine. I are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration,

including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory **arthritis** and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

IT **118072-93-8**, Zoledronate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of 3-oxo-4-aza-5α-androst-1-ene-17β-acetamide derivs. as androgen receptor modulators and their therapeutic uses)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:995989 CAPLUS

DN 142:747

TI Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

IN Hansen, Christian; Nilsson, Henrik

PA Nordic Bone A/S, Den.; Osteologix A/S; Christgau, Stephan

SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004098618	A2	20041118	WO 2004-DK327	20040506
	WO 2004098618	A3	20050324		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DK 2003-691	A	20030507		
	DK 2003-931	A	20030620		
	DK 2003-1819	A	20031209		
	US 2003-528548P	P	20031209		

AB A combination treatment, wherein a strontium-containing compound together with

one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone d. and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.

IT **118072-93-8**, Zoledronate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination treatment with strontium for prophylaxis and/or treatment of cartilage and/or bone conditions)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:965067 CAPLUS

DN 141:406039

TI Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

IN Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
	WO 2004096224	A3	20041216		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1473043	A1	20041103	EP 2003-9587	20030429
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	EP 2003-9587	A	20030429		
	EP 2004-508	A	20040113		
	EP 2004-1171	A	20040121		

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or

co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT **118072-93-8**, Zoledronic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:802699 CAPLUS

DN 141:294695

TI Osteoclast precursor cells as biomarkers for inflammatory joint diseases and related diagnostic and therapeutic methods

IN Ritchlin, Christopher T.; Haas-Smith, Sally; Schwarz, Edward

PA University of Rochester, USA

SO PCT Int. Appl., 214 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082635	A2	20040930	WO 2004-US8168	20040315
	WO 2004082635	A3	20050811		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004209316	A1	20041021	US 2004-799345	20040312
PRAI	US 2003-454573P	P	20030314		
	US 2004-799345	A	20040312		

AB The invention discloses that the increase in osteoclast cells is preceded by an increase of osteoclast precursor cells in the peripheral blood of a subject with an inflammatory joint disease. The invention thereby discloses methods of diagnosing inflammatory joint disease and therapeutic methods for inflammatory joint disease among methods and compns. related to osteoclasts and osteoclast precursor cells. Specifically, the invention claims use of cell surface markers CD14, CD11a, CD11b,

CD51/CD61, RANK, CCR1, CCR4, VCAM (CD106), VLA-4 (CD49d), CD16, MHC class II antigens, B7.1, B7.2, CD40 and c-fms to measure how many osteoclast precursor cells are in human tissue samples. Methods of diagnosing inflammatory joint diseases include measuring the number of osteoclast precursor cells, measuring osteoclast formation in culture, measuring the amount of tumor necrosis factor(TNF)-α secreted from cultured peripheral blood mononuclear cells (PBMC), measuring eroded bone material in cortical bone wafers after culturing with PBMC, and measuring mRNAs of osteoclast precursor cell markers. Similarly, the invention claims the osteoblast precursor cells and their markers in methods for monitoring therapies with anti-inflammatory agents. FACS characterization and an osteoclastogenesis assay of human TNF-transgenic mice showed that high levels of CD11b can be used as a representative marker for osteoclast precursors in the spleen. Injection of TNFα into wild-type mice induced a change in tissue distribution of CD11bhi cells similar to that observed in blood and spleen of the TNF-transgenic mice. These results suggested that redistribution of CD11bhi osteoclast precursors from bone marrow to circulation could be a mechanism for TNFα-induced erosive **arthritis**. In one example, PMBC from psoriatic **arthritis** patients were cultured to determine the osteoclast precursor cell frequency before and after anti-TNF-α therapy with Enbrel (etanercept) and infliximab. As determined by FACS of CD14/CD11b staining, the frequency of osteoclast precursors was significantly reduced in PMBC after anti-TNF therapy. Figures show a systemic lupus erythematosus-tumor necrosis factor transcriptome in blood leukocytes from children.

IT **118072-93-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osteoclast precursor cells and cell surface-associated proteins as biomarkers for inflammatory joint diseases and related diagnostic and therapeutic methods)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:642446 CAPLUS

DN 142:148138

TI Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced **arthritis**

AU Sims, Natalie A.; Green, Jonathan R.; Glatt, Markus; Schlict, Stephen; Martin, T. John; Gillespie, Matthew T.; Romas, Evan

CS St. Vincent's Hospital, University of Melbourne, Melbourne, Australia

SO Arthritis & Rheumatism (2004), 50(7), 2338-2346
CODEN: ARHEAW; ISSN: 0004-3591

PB John Wiley & Sons, Inc.

DT Journal

LA English

AB Objective: To study the effect of zoledronic acid (ZA) on synovial inflammation, structural joint damage, and bone metabolism in rats during the effector phase of collagen-induced **arthritis** (CIA). Methods: CIA was induced in female dark agouti rats. At the clin. onset of CIA, rats were assigned to treatment with vehicle or single s.c. doses of ZA (1.0, 10, 50, or 100 μg/kg). Clin. signs in all 4 paws were scored on

a daily basis. After 2 wk, the joints in the hind paws were assessed using plain radiographs, microfocal computed tomog. (micro-CT), histol. scoring, and histomorphometry, and the serum levels of type I collagen crosslinks were measured by ELISA. Results: Although ZA mildly exacerbated synovitis, it effectively suppressed structural joint damage. At doses of ≥10 μg/kg, ZA significantly reduced radiog. bone erosions, Larsen scores, and juxtaarticular trabecular bone loss as quantified by micro-CT. ZA prevented increased type I collagen (bone) breakdown in CIA and diminished histol. scores of focal bone erosion by up to 80%. Increases in the percentage of eroded surface, osteoclast surface, and osteoclast nos. associated with CIA were prevented by ZA, even though synovitis scores were unchanged. Conclusion: Single doses (≥10 μg/kg) of ZA strikingly reduced focal bone erosions and juxtaarticular trabecular bone loss, although synovitis was mildly exacerbated. Targeting osteoclasts with ZA may therefore be an effective strategy for preventing structural joint damage in **rheumatoid arthritis**.

IT **118072-93-8**, Zoledronic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(single dose of zoledronic acid effectively reduced focal bone erosions and juxtaarticular trabecular bone loss, protected against structural joint damage, although synovitis was mildly exacerbated during effector phase in CIA rat model)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:642445 CAPLUS

DN 142:148137

TI Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated **arthritis**

AU Herrak, Petra; Goertz, Birgit; Hayer, Silvia; Redlich, Kurt; Reiter, Erika; Gasser, Juerg; Bergmeister, Helga; Kollias, Giorgos; Smolen, Josef S.; Schett, Georg

CS University of Vienna, Vienna, Austria

SO Arthritis & Rheumatism (2004), 50(7), 2327-2337
CODEN: ARHEAW; ISSN: 0004-3591

PB John Wiley & Sons, Inc.

DT Journal

LA English

AB Objective: Increased osteoclast activity is a key factor in bone loss in **rheumatoid arthritis** (RA). This suggests that osteoclast-targeted therapies could effectively prevent skeletal damage in patients with RA. Zoledronic acid (ZA) is one of the most potent agents for blocking osteoclast function. We therefore investigated whether ZA can inhibit the bone loss associated with chronic inflammatory conditions. Methods: Human tumor necrosis factor (TNF)-transgenic (hTNFtg) mice, which develop severe destructive **arthritis** as well as osteoporosis, were treated with phosphate buffered saline, single or repeated doses of

ZA, calcitonin, or anti-TNF, at the onset of **arthritis**. Results: Synovial inflammation was not affected by ZA. In contrast, bone erosion was retarded by a single dose of ZA (-60%) and was almost completely blocked by repeated administration of ZA (-95%). Cartilage damage was partly inhibited, and synovial osteoclast counts were significantly reduced with ZA treatment. Systemic bone mass dramatically increased in hTNFtg mice after administration of ZA, which was attributable to an increase in trabecular number and connectivity. In addition, bone resorption parameters were significantly lowered after administration of ZA. Calcitonin had no effect on synovial inflammation, bone erosion, cartilage damage, or systemic bone mass. Anti-TNF entirely blocked synovial inflammation, bone erosion, synovial osteoclast formation, and cartilage damage but had only minor effects on systemic bone mass. Conclusion: ZA appears to be an effective tool for protecting bone from arthritic damage. In addition to their role in antiinflammatory drug therapy, modern bisphosphonates are promising candidates for maintaining joint integrity and reversing systemic bone loss in patients with **arthritis**.

IT **118072-93-8**, Zoledronic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ZA did not affect synovial inflammation, retarded bone erosion, partly inhibited cartilage damage, reduced synovial osteoclast count, bone resorption parameters, increased systemic bone mass in human TNFtg mouse with **arthritis**)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412812 CAPLUS
DN 140:406808
TI Preparation of carbonylamino-benzimidazoles as selective androgen receptor modulators
IN Kim, Yuntae; Spencer, Keith L.; Hanney, Barbara; Duggan, Mark E.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041277	A1	20040521	WO 2003-US34345	20031028

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2504044 AA 20040521 CA 2003-2504044 20031028
EP 1581217 A1 20051005 EP 2003-777969 20031028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-422914P P 20021101
WO 2003-US34345 W 20031028
OS MARPAT 140:406808
GI



I



II

AB Carbonylamino-benzimidazoles (shown as I; variables defined below; e.g. II) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compds. are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. Although the methods of preparation are not claimed, 6 example prepns. and characterization data for .apprx.150 examples of I are included; nearly all examples contain the thiazol-4-yl group at the 2 position of the benzimidazole. For example, II was prepared from 3-fluorophenethylamine, 1,1'-carbonyldiimidazole and [2-(thiazol-4-yl)-3H-benzimidazol-5-yl]amine, the latter of which was prepared from thiazole-4-carboxylic acid and (4-amino-3-nitrophenyl)carbamic acid tert-Bu ester (preparation described) via amide formation followed by cyclization in 20% aqueous AcOH. For I: R1 = aryl or heterocyclyl; R2 = -(C:O)NR5R6, -(C:O)a(C1-10)alkyl, -(C:O)a(C2-8)alkenyl, -(C:O)a(C2-8)alkynyl, -(C:O)a(C3-10)cycloalkyl, -(C:O)a(C3-8)heterocyclyl, and -(C:O)aaryl; R3 = H, halogen, -(C:O)aOb(C1-10)alkyl, -(C:O)aOb(C2-8)alkenyl, -(C:O)aOb(C2-8)alkynyl, -(C:O)aOb(C3-10)cycloalkyl, -(C:O)aOb(C3-8)heterocyclyl, -(C:O)aObaryl, -(C:O)aNR5R6, -Ob(C:O)NR5R6, -NR5(C:O)aObRb, -NR5(C:O)NR5R6, -NR5S(O)2Rb, -(C:O)OH, trifluoromethoxy, trifluoroethoxy, -Ob(C1-10)perfluoroalkyl, -S(O)2Ob(C1-10)alkyl, -S(O)2Ob(C2-8)alkenyl, -S(O)2Ob(C2-8)alkynyl,

-S(O)2Ob(C3-10)cycloalkyl, -S(O)2Ob(C3-8)heterocyclyl, -S(O)2Obaryl, -NR5S(O)2NR5R6, -CN, -NO2, oxo, and -OH; a = 0-1; b = 0-1; addnl. details are given in the claims.

IT **118072-93-8**, Zoledronate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of carbonylamino-benzimidazoles as selective androgen receptor modulators)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:354800 CAPLUS

DN 140:350571

TI Method of administering bisphosphonates for the treatment of **rheumatoid arthritis**

IN Sloan, Victor

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004035061	A1	20040429	WO 2003-EP11380	20031014
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2501381	AA	20040429	CA 2003-2501381	20031014
	EP 1553958	A1	20050720	EP 2003-772213	20031014
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015328	A	20050816	BR 2003-15328	20031014
PRAI	US 2002-418555P	P	20021015		
	WO 2003-EP11380	W	20031014		

OS MARPAT 140:350571

AB Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivs., can be used with satisfactory results for treatment of **rheumatoid arthritis** by intermittent administration, wherein the periods between bisphosphonate administrations are from about 2 mo up to about 4 mo, e.g. once every 3 mo.

IT **118072-93-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bisphosphonate administration for treatment of **rheumatoid arthritis**)

RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:991344 CAPLUS
DN 140:42461
TI Preparation of asparagine-derived 1,5-disubstituted imidazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of eye and bone diseases
IN Billot, Xavier; Young, Robert N.
PA Merck Frosst Canada & Co., Can.
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103664	A1	20031218	WO 2003-CA842	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487977	AA	20031218	CA 2003-2487977	20030603
	EP 1513523	A1	20050316	EP 2003-727101	20030603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-386641P	P	20020606		
	WO 2003-CA842	W	20030603		

OS MARPAT 140:42461
GI



I



II

AB The invention relates to imidazolidinones I [X is a bond, O or S; R1 is OH, CN, carboxyalkyl, CF2SO2NH2, SO2NH2, PO3H2, heterocyclyl, etc.; R2 is H, aryl, or alkyl; R3, R4 are H, halo, or alkyl; R5 is (hetero)aryl or (hetero)cycloalkyl or alkyl substituted by these groups; CR6R7 is CO or CH(OH); Z is (CRb2)0-4 or CRb:CRb, where Rb is H, halo, alkyl, or cycloalkyl; n is 0-4] or their pharmaceutically-acceptable salts, enantiomers, diastereomers, prodrugs or mixts., which are potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, and their use in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye and for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, R-asparagine-derived benzyl (4R)-3-(6-cyanohexyl)-4-formyl-2-oxoimidazolidine-1-carboxylate was treated with PhCH2COCH2P(O)(OMe)2, NaBH4, and Bu3SnN3 to afford tetrazole derivative II.

IT **118072-93-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical ingredient; preparation of asparagine-derived imidazolidinone derivs. for use as EP4 receptor agonists in treatment of eye and bone diseases)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:757525 CAPLUS
DN 139:277056
TI Preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivatives as androgen receptor modulators
IN Meissner, Robert S.; Perkins, James J.

PA Merck & Co., Inc., USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003077919	A1	20030925	WO 2003-US8277	20030307
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2478186	AA	20030925	CA 2003-2478186	20030307
	EP 1485095	A1	20041215	EP 2003-714228	20030307
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	BR 2003008355	A	20050125	BR 2003-8355	20030307
	US 2005165039	A1	20050728	US 2003-507239	20030307
	JP 2005526082	T2	20050902	JP 2003-575972	20030307
PRAI	US 2002-363822P	P	20020313		
	WO 2003-US8277	W	20030307		

OS MARPAT 139:277056
GI



I



II

AB Fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs., such as I [a-b = CF:CH, CHFCH2, CF2CH2; R1 = H, CH2OH, (un)substituted alkyl; R2 = H, alkyl; R3 = alkyl, cycloheteroalkyl, aryl, heteroaryl; R2R3 = 5 or 6-membered ring fused with a 5- or 6-membered aromatic ring system having 0-2 heteroatoms], or a pharmaceutically acceptable salt or an enantiomer thereof, were prepared for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, 4-aza-androstan-3-one-17β-carboxamide derivative II, was prepared via a multiple step reaction sequence starting from 4-methyl-4-aza-androstan-3-one-17-carboxylic acid Me ester and 2-fluoro-benzylamine. The prepared compds. are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. I are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration,

including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory **arthritis** and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

IT **118072-93-8**, Zoledronate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs. as androgen receptor modulators and their therapeutic uses)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:652131 CAPLUS

DN 139:214237

TI Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

IN Scaramuzzino, Giovanni

PA Italy

SO Eur. Pat. Appl., 313 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI EP 2002-425075		20020213		

GI



II

AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ-tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thoinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 = COCH2CH(M2)CH2N+Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, α-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT **586348-36-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)

RN 586348-36-9 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-, mononitrate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 118072-93-8
CMF C5 H10 N2 O7 P2



CM 2

CRN 7697-37-2
CMF H N O3



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:454048 CAPLUS
DN 139:30847
TI EP4 receptor agonists, preparation thereof, pharmaceutical compositions, and therapeutic uses
IN Ogidigben, Miller J.; Young, Robert N.; Billot, Xavier; Metters, Kathleen M.; Slipetz, Deborah M.
PA Merck & Co., Inc., USA; Merck Frosst Canada & Co.
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003047417	A2	20030612	WO 2002-US38039	20021127
	WO 2003047417	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2466751	AA	20030612	CA 2002-2466751	20021127
	EP 1453503	A2	20040908	EP 2002-784629	20021127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005519879	T2	20050707	JP 2003-548683	20021127
	US 2004204590	A1	20041014	US 2004-493649	20040422
PRAI	US 2001-337228P	P	20011203		
	WO 2002-US38039	W	20021127		

OS MARPAT 139:30847
AB The invention discloses potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, formulations thereof, preparation thereof, and use thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. The invention further discloses the use of these compds. for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
IT **118072-93-8**, Zoledronate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EP4 receptor agonists, preparation, pharmaceutical compns., therapeutic uses, and use with other agents)
RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:794290 CAPLUS
DN 137:284400
TI Bisphosphonate compounds for inhibiting farnesyl diphosphate synthase
IN Bergstrom, James D.; Reszka, Alfred A.; Rodan, Gideon A.
PA Merck & Co., Inc., USA
SO U.S. Pat. Appl. Publ., 11 pp., Cont. of U. S. Ser. No. 513,150.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002151459	A1	20021017	US 2002-121465	20020411
	US 2004235797	A1	20041125	US 2004-877094	20040625
PRAI	US 2000-513150	A1	20000225		
	US 2002-121465	A1	20020411		

OS MARPAT 137:284400
AB The present invention relates to methods for identifying compds. useful as inhibitors of farnesyl diphosphate synthase. More particularly, the compds. so identified are useful for inhibiting bone resorption. The present invention also relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl diphosphate synthase inhibitor. Thus, tablets contained farnesyl diphosphate synthase inhibitor 0.10-10, anhydrous lactose 71.32, Mg stearate 1.0, Croscarmellose sodium 2.0, and microcryst. cellulose qs 200 mg.
IT **118072-93-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bisphosphonate compds. for inhibiting farnesyl diphosphate synthase)
RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:428720 CAPLUS
DN 137:746
TI Use of bisphosphonates for pain treatment
IN Fox, Alyson; Green, Jonathan; O'Reilly, Terence; Urban, Laszlo; Walker, Katharine
PA Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002043738	A2	20020606	WO 2001-EP13836	20011127
	WO 2002043738	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

CA 2427161	AA	20020606	CA 2001-2427161	20011127
AU 2002017061	A5	20020611	AU 2002-17061	20011127
EP 1339411	A2	20030903	EP 2001-998352	20011127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015696	A	20040210	BR 2001-15696	20011127
JP 2004514696	T2	20040520	JP 2002-545708	20011127
CN 1535152	A	20041006	CN 2001-819784	20011127
NZ 525871	A	20050429	NZ 2001-525871	20011127
ZA 2003003247	A	20040510	ZA 2003-3247	20030425
NO 2003002405	A	20030527	NO 2003-2405	20030527
US 2004063670	A1	20040401	US 2003-432847	20031002
PRAI GB 2000-29111	A	20001129		
WO 2001-EP13836	W	20011127		

OS MARPAT 137:746

AB A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumor patient, or a patient suffering from an inflammatory disease, comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient.

IT **118072-93-8**, Zoledronic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bisphosphonates for pain treatment)

RN 118072-93-8 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



L24 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:891342 CAPLUS

DN 135:55654

TI Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory **arthritis** are reduced by a bisphosphonate (zoledronate)

AU Pysklywec, Michael W.; Moran, Erica L.; Bogoch, Earl R.

CS Orthopaedic Research Laboratory, University of Toronto, Toronto, ON, M4Y 1J3, Can.

SO Journal of Orthopaedic Research (2000), 18(5), 734-738
CODEN: JOREDR; ISSN: 0736-0266

PB Journal of Bone and Joint Surgery, Inc.

DT Journal

LA English

AB An increased risk of fracture is a feature of **rheumatoid arthritis** and of animal models of inflammatory **arthritis**. The authors examined geometrical changes in the metaphyseal cortex of the distal femur in an animal model of inflammatory **arthritis**. Addnl., the authors examined the effect of a bisphosphonate in preventing

these changes. 5 Groups of rabbits were studied: normal controls, those with inflammatory **arthritis**, and 3 groups with **arthritis** treated with bisphosphonate. To determine geometrical properties, image anal. was performed on digitized cross sections of the femoral metaphyseal cortices. The results demonstrated that the posterior cortical wall was less thick in rabbits with **arthritis** than in normal rabbits and in the rabbits in the 3 bisphosphonate treatment groups. Moment of inertia about the lateral-medial axis was reduced in rabbits with **arthritis** compared with normal rabbits. Cross-sectional area was not different between groups. The changes suggest a mechanism of weakening of bone in **arthritis**; when the results are coupled with results of previous porosity studies, severe directional weakness is apparent. Bisphosphonate was effective in preserving bone integrity in inflammatory **arthritis**.

IT **118072-93-8**, Zoledronate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(zoledronate reduces **arthritis**-induced geometrical changes in distal femoral metaphysis)

RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:666718 CAPLUS
DN 133:252041
TI Preparation of amine derivatives as cathepsin K and cathepsin S inhibitors and in treating pathology and/or symptomatology of diseases caused by cysteine protease activity
IN Link, John O.; Martelli, Arnold J.; Martichonok, Valeri; Patterson, John W.; Saunders, Oliver L.; Zipfel, Sheila
PA Axys Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000055144	A1	20000921	WO 2000-US6885	20000315
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367352	AA	20000921	CA 2000-2367352	20000315

	EP 1161422	A1	20011212	EP 2000-916397	20000315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009044	A	20020115	BR 2000-9044	20000315
	TR 200103335	T2	20020422	TR 2001-200103335	20000315
	JP 2002539201	T2	20021119	JP 2000-605574	20000315
	EE 200100486	A	20030217	EE 2001-486	20000315
	US 6576630	B1	20030610	US 2000-525507	20000315
	AU 774664	B2	20040701	AU 2000-37507	20000315
	AU 2000037507	A5	20001004		
	EP 1516877	A1	20050323	EP 2004-15656	20000315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	ZA 2001007496	A	20021211	ZA 2001-7496	20010911
	NO 2001004483	A	20011101	NO 2001-4483	20010914
	BG 105969	A	20020531	BG 2001-105969	20011002
	HR 2001000736	A1	20021231	HR 2001-736	20011012
	US 2003232864	A1	20031218	US 2003-354888	20030128
PRAI	US 1999-124421P	P	19990315		
	EP 2000-916397	A3	20000315		
	US 2000-525507	A1	20000315		
	WO 2000-US6885	W	20000315		

OS MARPAT 133:252041

GI



I



II

AB Title compds. [I; A = heteromonocyclic ring containing 5-6 member; fused heteropolycyclic ring containing 8-14 member; X1 = C, CH; X2 = bond, NHCH2CO, NHCH2CH2SO2, alkylamino; R1 = alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl; R2 = H, alkyl; R3 = alkyl; R4 = H, alkyl; R3R4 = cycloalkylene, heterocycloalkylene; R5 = H; R6 = H; R5R6 = oxo; R7 = CN, Cl, Br, F, NO2, H; R8 = alkyl, alkylidene, CN, Cl, F, Br, NO2; n = 0, 1, 2, 3], N-oxide derivs., prodrug derivs., protected derivs., individual isomers, mixts. of isomers, and pharmaceutically acceptable salts and compns. with bisphosphonic acids or acid esters as excipients are prepared as cathepsin K and cathepsin S inhibitors. Title compds. are administering to animal in treating diseases which cysteine protease activity contributes to the pathol. and/or symptomatol. The diseases are autoimmune disorder, allergic disorder, allogeneic immune response, excessive elastolysis, cardiovascular disorders, fibril formation, etc. Thus, the title compound II was prepared

IT **118072-93-8**

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(preparation of amine derivs. as cathepsin K and cathepsin S inhibitors

useful in disorders caused by cysteine protease activity)
RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:456892 CAPLUS
DN 133:68937
TI Interleukin-6 production inhibitors
IN Koike, Junzo; Funaba, Yuriko; Tanahashi, Masahiko; Okazaki, Seiji; Ito, Masatoshi
PA Toray Industries, Inc., Japan
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038693	A1	20000706	WO 1999-JP3346	19990623
	W: CA, CN, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2321864	AA	20000706	CA 1999-2321864	19990623
	EP 1057488	A1	20001206	EP 1999-926772	19990623
	R: DE, ES, FR, GB, IT				
	US 6579860	B1	20030617	US 2000-623014	20000927
PRAI	JP 1998-370150	A	19981225		
	WO 1999-JP3346	W	19990623		

OS MARPAT 133:68937
AB The invention relates to drugs effective in the prevention and treatment of diseases due to abnormal production of interleukin-6, which are interleukin-6 production inhibitors containing as the active ingredient methanebis-phosphonic acid derivs. and exhibit an inhibitory effect against the production of interleukin-6. These drugs can be expected to be effective in the prevention and treatment of diseases in which interleukin-6 participates, for example, thrombocytosis, inflammatory diseases, immune response disorders, osteoporosis, **rheumatoid arthritis**, hypercalcemia, multiple myeloma, cachexia and nephritis.
IT **118072-93-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin-6 production inhibitors for therapeutic use)
RN 118072-93-8 CAPLUS
CN Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	117.86	960.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-16.06	-16.06

STN INTERNATIONAL LOGOFF AT 17:33:41 ON 25 OCT 2005